Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.

Latest press releases

14 January 2019

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Results from this short clinical pharmacology trial inform and support further clinical development of ensifentr…

9 January 2019

Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
LONDON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharm…


Unique mechanism of action

Our breakthrough lead product, RPL554, is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases


Current share price


0.00 (0.00%)



-0.48 (-7.13%)


Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

T: +44 (0)203 283 4200



Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
ICR, Inc.
T: +1 646-277-1282

UK Investor relations contact
FTI Consulting
T: +44 (0)20 3727 1000

Nominated adviser and broker
Stifel Nicolaus Europe Limited
150 Cheapside
London EC2V 6ET
United Kingdom

T: +44 (0)207 710 7600


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us